Articles
Clinical Monographs
In-depth, citation-backed writing on clinical monographs. · 15 articles in Clinical Monographs
Does Pemvidutide Improve Alcohol Use Disorder Outcomes in Patients With Obesity — What Did the July 2026 RECLAIM Study Report?
Yes. The July 2026 RECLAIM Phase 2 trial reported that pemvidutide, a balanced GLP-1/glucagon dual receptor agonist developed by Altimmune, significantly reduced heavy drinking days and total alcohol consumption in adults with comorbid obesity and alcohol use disorder. Participants also achieved clinically meaningful weight loss, indicating simultaneous benefit across both conditions.
What Human Safety and Efficacy Data Support MOTS-c for Metabolic or Longevity Indications After the 2026 FDA Review?
As of 2026, MOTS-c lacks approved human clinical trial data for any metabolic or longevity indication. The available human evidence is limited to observational studies linking endogenous circulating MOTS-c levels to insulin sensitivity and aging phenotypes, one small exercise-intervention study, and preclinical mechanistic work. The FDA's 2026 review placed it under compounding scrutiny without an approved NDA.
What Do 2026 Obesity Analyses Reveal About Retatrutide's Efficacy and Safety Risk-Benefit Profile?
Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist in Phase 3 development. It demonstrated up to 24.2% mean body-weight reduction at 48 weeks in its pivotal Phase 2 trial. Emerging 2026 analyses confirm robust efficacy but flag dose-dependent gastrointestinal adverse events and a persistent resting heart-rate elevation as the primary safety signals requiring ongoing risk-benefit evaluation.